A Comparison of Infection Rates Between Two Surgical Sites
Does the use of chlorhexidine scrub prior to cutaneous surgery on the face increase the chances of toxicity to the eyes or ears? In addition, does the us eof chlorhexidine scrub on the face prior to cutaneous surgery decrease the chances of a post-operative wound infection?
Surgical Site Infection
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||A Comparative Assessment Between Two Surgical Sites of the Rate of Corneal Toxicity and Ototoxicity With the Use of Povidone-iodine Versus Chlorhexidine-alcohol for Facial Lesions Treated With Mohs Micrographic Surgery|
- Ocular and Ear Toxicities [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]Comparing ocular and ear toxicities between two institutions with differences in aseptic technique.
- Infection rates [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]compare the infections rates between two institutions with different skin prep practices
|Study Start Date:||January 2011|
|Study Completion Date:||August 2013|
|Primary Completion Date:||August 2013 (Final data collection date for primary outcome measure)|
The intent of this proposed prospective observational cohort study is to determine if there is a difference in the incidence of corneal toxicity and/or ototoxicity in study subjects undergoing Mohs micrographic surgery (MMS) on the face if a povidone-iodine preparation is used pre-operatively as compared to a chlorhexidine-alcohol preparation. It has recently been found that the use of a chlorhexidine-alcohol preparation is superior to the use of a povidone-iodine preparation in preventing post-operative surgical-site infections (SSI) in patients undergoing clean-contaminated surgery. However, the use of chlorhexidine on the face has previously been associated with corneal toxicity and ototoxicity. This study will help to further define previously reported risks of corneal toxicity and ototoxicity associated with the use of a chlorhexidine solution on the face.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01263262
|United States, Minnesota|
|Mayo Clinic in Rochester|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Jerry Brewer, MD||Mayo Clinic|